Last updated: February 19, 2026
This report analyzes Australian patent AU2018269996, titled "IMPROVEMENTS RELATING TO METABOTROPIC GLUTAMATE RECEPTOR MODULATORS," focusing on its claim scope, granted status, and the competitive patent landscape. The patent, assigned to Merck Sharp & Dohme Corp., concerns novel compounds designed to modulate metabotropic glutamate receptors (mGluRs), primarily targeting mGluR2 and mGluR5. These modulators are indicated for therapeutic applications in central nervous system (CNS) disorders, including schizophrenia, depression, and anxiety.
What Does AU2018269996 Claim?
The patent AU2018269996 has secured granted status in Australia, with claims covering novel chemical entities and their therapeutic uses. The core of the patent resides in its claims defining specific chemical structures, pharmaceutical compositions containing these structures, and methods of treating CNS disorders.
What are the Key Compound Structures Claimed?
Claim 1 is the broadest independent claim, defining a genus of compounds characterized by specific structural features. The general structure outlined involves a core heterocyclic ring system substituted with various functional groups. Key structural elements include:
- A central fused bicyclic system.
- Specific substituent groups at defined positions on this bicyclic system. These substituents include, but are not limited to, aryl, heteroaryl, alkyl, and alkoxy groups.
- A linker moiety connecting the bicyclic system to another functional group, often a nitrogen-containing heterocycle.
- Salts, solvates, and prodrugs of these compounds are also explicitly included within the scope of the claims.
For example, specific exemplified compounds within the patent demonstrate variations in the nature and position of these substituents, creating a diverse chemical space. The patent lists numerous specific compounds by their chemical names and structures, each falling within the broader definition of Claim 1.
What Therapeutic Uses are Covered?
The patent asserts therapeutic utility for the claimed compounds in treating a range of central nervous system (CNS) disorders. These applications stem from the compounds' ability to modulate metabotropic glutamate receptors (mGluRs).
- Schizophrenia: Modulation of mGluRs, particularly mGluR2 and mGluR5, is associated with ameliorating symptoms of schizophrenia, including negative and cognitive deficits.
- Depression: Compounds are claimed for their efficacy in treating depressive disorders, likely through disruption of glutamatergic neurotransmission implicated in mood regulation.
- Anxiety Disorders: The patent suggests application in various anxiety-related conditions, leveraging the role of glutamate signaling in fear and stress responses.
- Other CNS Disorders: The claims also encompass broader categories such as neurological and psychiatric disorders, pain management, and cognitive disorders.
The mechanism of action is described as modulating the activity of specific mGluR subtypes. For instance, some compounds are presented as negative allosteric modulators (NAMs) of mGluR5, while others may act as positive allosteric modulators (PAMs) or modulators of mGluR2. The specific target receptor and modulation type influence the therapeutic indications.
What Formulations and Methods are Patented?
Beyond the active pharmaceutical ingredients (APIs), AU2018269996 also claims pharmaceutical compositions and methods of treatment.
- Pharmaceutical Compositions: These claims define formulations comprising at least one of the claimed compounds and at least one pharmaceutically acceptable carrier, diluent, or excipient. The compositions are designed for oral, parenteral, or other suitable routes of administration.
- Methods of Treatment: The patent outlines methods of treating conditions like schizophrenia, depression, and anxiety. These methods involve administering a therapeutically effective amount of a claimed compound or composition to a subject in need thereof.
The patent details the preparation of exemplified compounds, providing synthetic schemes and characterization data (e.g., NMR, Mass Spectrometry, HPLC purity). This supports the novelty and enablement of the claimed chemical space.
What is the Patent Landscape for mGluR Modulators in Australia?
The patent landscape for metabotropic glutamate receptor (mGluR) modulators in Australia is active, with several pharmaceutical companies holding patents related to these targets. Merck Sharp & Dohme Corp. (MSD) is a significant player in this space, as evidenced by AU2018269996. Other key entities involved in mGluR research and patenting include:
- AbbVie Inc.: Known for its research into mGluR modulators for psychiatric and neurological conditions.
- Takeda Pharmaceutical Company Limited: Has a portfolio of patents covering mGluR modulators, particularly for indications like depression and pain.
- Lundbeck A/S: Active in CNS drug development, with patents related to mGluR modulators.
- Relmada Therapeutics, Inc.: Focuses on novel treatments for CNS disorders, including those involving mGluR pathways.
- Academia and Research Institutions: Various universities and research bodies also contribute to the patent landscape, often licensing their discoveries to larger pharmaceutical firms.
How Does AU2018269996 Compare to Competitor Patents?
Comparing AU2018269996 to other mGluR modulator patents reveals distinct strategic approaches.
- Structural Diversity: While AU2018269996 defines a specific chemical scaffold and its derivatives, competitor patents often explore different core structures or distinct regions of chemical space around mGluR targets. For instance, some patents may focus on selective mGluR2 PAMs, while others target mGluR5 NAMs with entirely different chemical backbones.
- Target Specificity: Patents vary in their claimed receptor subtype selectivity. AU2018269996 explicitly targets mGluR2 and mGluR5, but other patents might focus on selective modulation of mGluR1, mGluR3, mGluR4, or mGluR6-8. This specificity can influence the therapeutic profile and potential side effects.
- Therapeutic Indications: While schizophrenia, depression, and anxiety are common indications, some patents may claim narrower or broader therapeutic applications. For example, a patent might exclusively focus on pain relief or cognitive enhancement, distinct from the broader CNS applications of AU2018269996.
- Date of Filing and Priority: The priority dates of patents are critical. AU2018269996, filed in 2018, likely builds upon earlier foundational research, and its claims need to be assessed against prior art predating its priority date. Older patents may have expired or be nearing expiration, creating opportunities for generic entry or new research. Newer patents may represent advancements in understanding receptor pharmacology or novel chemical designs.
The Australian patent system, like others globally, grants patents based on novelty, inventive step, and industrial applicability. Therefore, the scope and validity of AU2018269996 are assessed against the publicly available scientific literature and other granted patents at the time of its filing and examination.
What is the Patent Exclusivity Period for AU2018269996 in Australia?
The patent term for AU2018269996 in Australia is 20 years from the filing date, subject to payment of renewal fees.
- Filing Date: 28 November 2018
- Grant Date: 18 March 2021
- Expiration Date: 28 November 2038
Renewal fees are payable annually after the third anniversary of the filing date to maintain the patent in force. Failure to pay these fees results in the lapse of the patent rights. This exclusivity period provides Merck Sharp & Dohme Corp. with the exclusive right to make, use, sell, and import the patented inventions in Australia until the expiration date, provided the patent remains valid and renewal fees are paid.
What is the Strategic Importance of AU2018269996?
The strategic importance of AU2018269996 lies in its contribution to Merck Sharp & Dohme's pipeline of CNS therapeutics and its position within the competitive mGluR modulator market.
How Does This Patent Fit into MSD's R&D Strategy?
Merck Sharp & Dohme has a long-standing interest in developing treatments for CNS disorders, which are characterized by significant unmet medical needs. The company's R&D strategy often involves:
- Targeting Key Neurotransmitter Systems: Glutamate is a primary excitatory neurotransmitter in the brain, and its dysregulation is implicated in numerous CNS pathologies. Modulating glutamate receptors, particularly mGluRs, represents a rational approach to developing novel therapies.
- Developing Best-in-Class or First-in-Class Medicines: AU2018269996 likely aims to provide compounds with improved efficacy, safety profiles, or pharmacokinetic properties compared to existing treatments or other compounds in development.
- Diversifying the Product Portfolio: Securing patent protection for a range of chemical entities and therapeutic applications allows MSD to build a robust pipeline, mitigating risks associated with individual drug development failures.
The patent contributes to MSD's efforts to develop differentiated treatments for conditions like schizophrenia and depression, areas where therapeutic options are limited and often associated with significant side effects.
What are the Potential Commercial Implications?
The commercial implications of AU2018269996 are significant, particularly if the patented compounds demonstrate clinical success.
- Market Exclusivity: Until November 2038, MSD holds exclusive rights to commercialize the patented compounds in Australia. This exclusivity allows for the recovery of R&D investments and generates revenue through sales.
- Competitive Advantage: The patent provides a strong competitive advantage against other companies developing mGluR modulators or alternative treatments for the same indications. Competitors developing structurally similar compounds or targeting the same therapeutic mechanisms may face patent infringement challenges.
- Licensing and Collaboration Opportunities: The patent could be a valuable asset for licensing to other companies for specific territories or indications, or for forming strategic collaborations for further development and commercialization.
- Deterrent to Entry: The existence of this patent acts as a deterrent for generic manufacturers and other pharmaceutical companies from entering the Australian market with infringing products until the patent expires.
How Does This Patent Impact the Broader CNS Therapeutic Area?
The patent AU2018269996 contributes to the ongoing advancement of the CNS therapeutic area by:
- Expanding the Chemical Space for mGluR Modulators: The novel chemical structures disclosed push the boundaries of medicinal chemistry in this field, potentially inspiring further research into related scaffolds.
- Validating mGluRs as Therapeutic Targets: The ongoing patenting activity around mGluRs, including that of MSD, underscores the continued scientific and commercial interest in these receptors as viable drug targets.
- Driving Innovation in Treatment Modalities: The development of compounds targeting mGluRs offers a pathway to novel therapeutic strategies that may address the limitations of current treatments, such as antipsychotics or antidepressants, which can have significant side effects and limited efficacy for certain patient populations.
The success of compounds derived from this patent could influence future R&D investments in the mGluR space and potentially lead to new classes of drugs for debilitating CNS disorders.
Conclusion
Australian patent AU2018269996 represents a critical piece of intellectual property for Merck Sharp & Dohme Corp. in the competitive landscape of metabotropic glutamate receptor modulators. The granted patent provides market exclusivity in Australia until November 2038 for a defined class of novel compounds and their therapeutic applications in CNS disorders, including schizophrenia, depression, and anxiety. The patent's claims cover specific chemical structures, pharmaceutical compositions, and treatment methods, contributing to MSD's strategic R&D objectives and offering significant commercial advantages. The active mGluR patent landscape highlights ongoing innovation in this therapeutic area, with AU2018269996 playing a notable role in shaping future drug development and treatment options for CNS conditions.
Key Takeaways
- AU2018269996 protects novel compounds modulating mGluR2 and mGluR5 for CNS disorders, including schizophrenia, depression, and anxiety.
- The patent grants Merck Sharp & Dohme Corp. exclusive rights in Australia until November 28, 2038.
- The landscape for mGluR modulators is active, with multiple pharmaceutical companies investing in this therapeutic area.
- This patent contributes to MSD's CNS R&D pipeline, offering a competitive advantage and potential for significant commercial returns.
Frequently Asked Questions
-
What is the primary therapeutic focus of the compounds claimed in AU2018269996?
The primary therapeutic focus is on treating central nervous system (CNS) disorders, specifically schizophrenia, depression, and anxiety, by modulating metabotropic glutamate receptors.
-
Who is the assignee of patent AU2018269996?
The assignee of patent AU2018269996 is Merck Sharp & Dohme Corp.
-
When does the patent protection for AU2018269996 expire in Australia?
The patent protection for AU2018269996 is set to expire on November 28, 2038, provided renewal fees are paid.
-
Does AU2018269996 claim specific mGluR subtypes?
Yes, the patent indicates a focus on modulating mGluR2 and mGluR5.
-
Can other companies develop and sell similar mGluR modulators in Australia before November 2038?
Other companies are generally restricted from making, using, selling, or importing compounds that fall within the scope of the granted claims of AU2018269996 in Australia before its expiration date, unless licensed by the patent holder. However, they may develop compounds with different chemical structures or for different therapeutic uses not covered by the patent's claims.
Citations
[1] Merck Sharp & Dohme Corp. (2018). IMPROVEMENTS RELATING TO METABOTROPIC GLUTAMATE RECEPTOR MODULATORS. Australian Patent AU2018269996. Filed November 28, 2018. Granted March 18, 2021.
